Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: European Journal of Nuclear Medicine and Molecular Imaging, 52, S. 970-978
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2025
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Springer Science and Business Media LLC
- (wann)
-
2025
- Urheber
-
Gäble, Alexander
Dierks, Alexander
Rinscheid, Andreas
Patt, Marianne
Wienand, Georgine
Pfob, Christian H.
Kircher, Malte
Fukushima, Kazuhito
Nikolić, Ana Antić
Enke, Johanna S.
Janzen, Tilman
Steinestel, Julie
Kempter, Hildegard
Trepel, Martin
Weckermann, Dorothea
Lapa, Constantin Frederik Victor
Bundschuh, Ralph A.
- DOI
-
10.1007/s00259-024-06959-5
- URN
-
urn:nbn:de:bvb:384-opus4-1171269
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gäble, Alexander
- Dierks, Alexander
- Rinscheid, Andreas
- Patt, Marianne
- Wienand, Georgine
- Pfob, Christian H.
- Kircher, Malte
- Fukushima, Kazuhito
- Nikolić, Ana Antić
- Enke, Johanna S.
- Janzen, Tilman
- Steinestel, Julie
- Kempter, Hildegard
- Trepel, Martin
- Weckermann, Dorothea
- Lapa, Constantin Frederik Victor
- Bundschuh, Ralph A.
- Universität Augsburg
- Springer Science and Business Media LLC
Entstanden
- 2025
Ähnliche Objekte (12)
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography